STAT1 and renal carcinoma: By targeting both TNKS1 and CDK8, TCS9725 is expected to disrupt critical signaling pathways involved in renal cancer progression, including STAT1, β-Catenin, and TGFβ1-Smad signaling, which are known to drive cancer cell proliferation and metastasis.